secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolent Health, Inc. (EVH)
CIK:        0001628908
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0001628908-24-000015
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolent Health Q4 revenue $556M, FY revenue $1.96B (+45%); net loss ($142M), adj EBITDA $194.7M (+84%)
--------------------------------------------------------------------------------

- Full year 2023 revenue of $1,963.9M, up 45% YoY; net loss of $(142.3)M (net loss margin -7.2%).
- Adjusted EBITDA of $194.7M, up 84% YoY; cash flow from operations of $142.6M.
- Q4 2023 revenue $556.1M, net loss $(41.4)M, adjusted EBITDA $48.1M (8.6% margin).
- Initial 2024 outlook: revenue growth ~25% at midpoint, consistent with long-term targets.
- Announced four new revenue agreements, including first comprehensive oncology bundle and first Performance Suite for advanced imaging.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628908/000162890824000015/0001628908-24-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628908/000162890824000015/evh-20240222.htm
  HTML page:      https://secwatch.observer/filing/0001628908-24-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer